DEA Places Seizure Treatment Drug Into Schedule V
The Drug Enforcement Administration is placing the newly approved drug ganaxolone in Schedule V of the Controlled Substances Act, it said in an interim final rule. Effective June 1, ganaxolone, which was granted approval by the FDA in March, is…
Sign up for a free preview to unlock the rest of this article
Communications Daily is required reading for senior executives at top telecom corporations, law firms, lobbying organizations, associations and government agencies (including the FCC). Join them today!
subject to new registration, labeling, record-keeping, and import and export requirements. DEA is accepting comments on the rule until July 1.